Informações de GSK plc | Histórico, dados financeiros e desempenho de mercado

Mais detalhes de GSK plc Empresa

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes the lead molecule IDRX-42, highly selective tyrosine kinase inhibitor (TKI) that is designed to improve patients with gastrointestinal stromal tumors (GIST).

Informações da empresa

Código da empresaGSK

Nome da EmpresaGSK plc

Data de listagemMay 22, 1972

Fundado em1999

CEOMs. Deborah Waterhouse

Número de funcionários68629

Tipo de títulosOrdinary Share

Fim do ano fiscalMay 22

Endereço980 Great West Road

CidadeBRENTFORD

Bolsa de valoresLondon Stock Exchange

PaísUnited Kingdom

Código postalTW8 9GS

Telefone442080475000

Sitehttps://www.gsk.com/

Código da empresaGSK

Data de listagemMay 22, 1972

Fundado em1999

Executivos da empresa

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Hal V. Barron, M.D.

Non-Executive Director

644.04K

--

Ms. Shobie Ramakrishnan

Chief Digital and Technology Officer

483.75K

+7.69%

Mr. Charles A. (Charlie) Bancroft

Senior Independent Non-Executive Director

34.31K

+0.51%

Dr. Jesse Goodman, M.D.

Non-Executive Independent Director, Scientific and Medical Expert

15.98K

+0.14%

Ms. Elizabeth McKee (Liz) Anderson

Independent Non-Executive Director

2.45K

+1.07%

Dr. Jeannie Lee

Independent Non-Executive Director and Scientific & Medical Expert

1.05K

+0.96%

Dr. Harry C. (Hal) Dietz

Independent Non-Executive Director, Scientific and Medical Expert

--

Mr. James Ford

Senior Vice President, Group General Counsel, Legal and Compliance

--

Ms. Sally Jackson

Senior Vice President - Global Communications and CEO Office

--

Dr. Tony Wood, Ph.D.

Chief Scientific Officer

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Hal V. Barron, M.D.

Non-Executive Director

644.04K

--

Ms. Shobie Ramakrishnan

Chief Digital and Technology Officer

483.75K

+7.69%

Mr. Charles A. (Charlie) Bancroft

Senior Independent Non-Executive Director

34.31K

+0.51%

Dr. Jesse Goodman, M.D.

Non-Executive Independent Director, Scientific and Medical Expert

15.98K

+0.14%

Ms. Elizabeth McKee (Liz) Anderson

Independent Non-Executive Director

2.45K

+1.07%

Dr. Jeannie Lee

Independent Non-Executive Director and Scientific & Medical Expert

1.05K

+0.96%

Detalhamento da receita

Moeda: USDTempo de atualização: dom, 6 de abr

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Respiratory

9.22B

22.99%

HIV

9.06B

22.59%

Shingles

4.30B

10.72%

Established Vaccines

4.27B

10.64%

Immuno-inflammation

4.21B

10.51%

Other

9.04B

22.54%

Por RegiãoUSD

Nome

Receita

Proporção

US

20.93B

52.22%

Rest of world

18.25B

45.53%

UK

904.53M

2.26%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Respiratory

9.22B

22.99%

HIV

9.06B

22.59%

Shingles

4.30B

10.72%

Established Vaccines

4.27B

10.64%

Immuno-inflammation

4.21B

10.51%

Other

9.04B

22.54%

Acionista

Tempo de atualização: sex, 21 de fev

Estatísticas dos acionistas

Tipo

Estatísticas dos acionistas

Acionista

Proporção

Dodge & Cox

3.33%

Fidelity Management & Research Company LLC

2.13%

PRIMECAP Management Company

1.23%

Fisher Investments

0.92%

JTC Employer Solutions Trusteee Ltd

0.74%

Other

91.66%

Estatísticas dos acionistas

Acionista

Proporção

Dodge & Cox

3.33%

Fidelity Management & Research Company LLC

2.13%

PRIMECAP Management Company

1.23%

Fisher Investments

0.92%

JTC Employer Solutions Trusteee Ltd

0.74%

Other

91.66%

Tipo

Acionista

Proporção

Investment Advisor

8.78%

Investment Advisor/Hedge Fund

6.23%

Hedge Fund

0.93%

Research Firm

0.71%

Bank and Trust

0.09%

Individual Investor

0.06%

Pension Fund

0.06%

Insurance Company

0.06%

Family Office

0.02%

Other

83.06%

Participação acionária institucional

Tempo de atualização: dom, 19 de jan

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q1

1444

354.89M

17.21%

+26.92M

2024Q4

1481

355.06M

17.14%

+27.38M

2024Q3

1472

319.97M

15.44%

-30.07M

2024Q2

1585

322.06M

15.54%

-29.11M

2024Q1

1617

318.91M

15.39%

-23.52M

2023Q4

1614

299.81M

14.57%

-35.71M

2023Q3

1570

293.92M

14.35%

-37.46M

2023Q2

1545

286.58M

13.99%

-41.88M

2023Q1

1546

281.08M

13.72%

-55.01M

2022Q4

1546

286.90M

13.32%

-22.15M

Ver Mais

Atividade dos acionistas

Nome

Ações detidas

Proporção

Variação

Var. %

Data

Dodge & Cox

68.44M

3.32%

+353.75K

+0.52%

Dec 31, 2024

Fidelity Management & Research Company LLC

43.77M

2.12%

+18.14M

+70.76%

Dec 31, 2024

PRIMECAP Management Company

25.26M

1.22%

+10.41M

+70.07%

Dec 31, 2024

Fisher Investments

18.84M

0.91%

+259.87K

+1.40%

Dec 31, 2024

JTC Employer Solutions Trusteee Ltd

20.28M

0.98%

-202.40K

-0.99%

Dec 31, 2024

Fidelity Institutional Asset Management

9.05M

0.44%

+5.68M

+168.17%

Dec 31, 2024

Goldman Sachs Asset Management, L.P.

8.85M

0.43%

+1.77M

+25.04%

Dec 31, 2024

T. Rowe Price International Ltd

7.57M

0.37%

+35.11K

+0.47%

Dec 31, 2024

State Street Global Advisors (US)

7.03M

0.34%

+247.17K

+3.65%

Dec 31, 2024

UBS Financial Services, Inc.

6.34M

0.31%

+5.69M

+871.38%

Dec 31, 2024

Ver Mais

ETFs Relacionados

Tempo de atualização: dom, 6 de abr

Nome

Proporção

The Opal International Dividend Income ETF

6.71%

VanEck Pharmaceutical ETF

4.7%

Keating Active ETF

3.52%

Brandes International ETF

3.27%

Sound Equity Dividend Income ETF

3.17%

Altrius Global Dividend ETF

1.9%

Pacer Global Cash Cows Dividend ETF

1.87%

USCF Dividend Income Fund

1.59%

Fidelity Blue Chip Value ETF

1.4%

Fidelity Women's Leadership ETF

1.08%

Ver Mais

The Opal International Dividend Income ETF

Proporção6.71%

VanEck Pharmaceutical ETF

Proporção4.7%

Keating Active ETF

Proporção3.52%

Brandes International ETF

Proporção3.27%

Sound Equity Dividend Income ETF

Proporção3.17%

Altrius Global Dividend ETF

Proporção1.9%

Pacer Global Cash Cows Dividend ETF

Proporção1.87%

USCF Dividend Income Fund

Proporção1.59%

Fidelity Blue Chip Value ETF

Proporção1.4%

Fidelity Women's Leadership ETF

Proporção1.08%

Dividendo

Um total de 20.79B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Feb 05, 2025

GSK.NB Approximate interim Cash Dividend of gross USD 0.400652 paid on Apr 10, 2025 going ex on Feb 21, 2025

Feb 21, 2025

Apr 10, 2025

Feb 21, 2025

Oct 30, 2024

GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024

Nov 15, 2024

Jan 09, 2025

Nov 15, 2024

Jul 31, 2024

GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Oct 10, 2024

Aug 16, 2024

May 01, 2024

GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024

May 17, 2024

Jul 11, 2024

May 16, 2024

Feb 01, 2024

GSK.NB Interim Cash Dividend of gross USD 0.404885 paid on Apr 11, 2024 going ex on Feb 22, 2024

Feb 23, 2024

Apr 11, 2024

Feb 22, 2024

Nov 01, 2023

GSK.NB Final Cash Dividend of gross USD 0.356356 paid on Jan 11, 2024 going ex on Nov 16, 2023

Nov 17, 2023

Jan 11, 2024

Nov 16, 2023

Jul 26, 2023

GSK.NB Interim Cash Dividend of gross USD 0.343532 paid on Oct 12, 2023 going ex on Aug 17, 2023

Aug 18, 2023

Oct 12, 2023

Aug 17, 2023

Apr 26, 2023

GSK.NB Interim Cash Dividend of gross USD 0.360944 paid on Jul 13, 2023 going ex on May 18, 2023

May 19, 2023

Jul 13, 2023

May 18, 2023

Feb 01, 2023

GSK.NB Interim Cash Dividend of gross USD 0.341883 paid on Apr 13, 2023 going ex on Feb 23, 2023

Feb 24, 2023

Apr 13, 2023

Feb 23, 2023

Nov 02, 2022

GSK.NB Final Cash Dividend of gross USD 0.334785 paid on Jan 12, 2023 going ex on Nov 17, 2022

Nov 18, 2022

Jan 12, 2023

Nov 17, 2022

Ver Mais

Desdobramento de ações

Data

Tipo

Proporção

Jun 24, 2022

Merger

5<4

Jun 24, 2022

Merger

5<4

Jun 24, 2022

Merger

5<4

Jun 24, 2022

Merger

5<4

Data

Tipo

Proporção

Jun 24, 2022

Merger

5<4

Jun 24, 2022

Merger

5<4

Jun 24, 2022

Merger

5<4

Jun 24, 2022

Merger

5<4

GSK plc

37.430USD

GSK plc

37.430

Visão Geral

Empresa